相似文献
1
Cancer immunotherapy targeting neoantigens.
Semin Immunol. 2016 Feb;28(1):22-7. doi: 10.1016/j.smim.2015.11.002. Epub 2015 Nov 30.
2
Immunopharmacogenomics towards personalized cancer immunotherapy targeting neoantigens.
Cancer Sci. 2018 Mar;109(3):542-549. doi: 10.1111/cas.13498. Epub 2018 Feb 14.
3
Neoantigen identification strategies enable personalized immunotherapy in refractory solid tumors.
J Clin Invest. 2019 Mar 5;129(5):2056-2070. doi: 10.1172/JCI99538. Print 2019 May 1.
4
The role of neoantigens in response to immune checkpoint blockade.
Int Immunol. 2016 Aug;28(8):411-9. doi: 10.1093/intimm/dxw019. Epub 2016 Apr 5.
5
Targeting neoantigens to augment antitumour immunity.
Nat Rev Cancer. 2017 Apr;17(4):209-222. doi: 10.1038/nrc.2016.154. Epub 2017 Feb 24.
6
Neoantigen prioritization based on antigen processing and presentation.
Front Immunol. 2024 Nov 6;15:1487378. doi: 10.3389/fimmu.2024.1487378. eCollection 2024.
7
Neoantigen: A New Breakthrough in Tumor Immunotherapy.
Front Immunol. 2021 Apr 16;12:672356. doi: 10.3389/fimmu.2021.672356. eCollection 2021.
8
Cancer Neoantigens.
Annu Rev Immunol. 2019 Apr 26;37:173-200. doi: 10.1146/annurev-immunol-042617-053402. Epub 2018 Dec 14.
9
Neoantigens in precision cancer immunotherapy: from identification to clinical applications.
Chin Med J (Engl). 2022 Jun 5;135(11):1285-1298. doi: 10.1097/CM9.0000000000002181.
10
Proteogenomics offers a novel avenue in neoantigen identification for cancer immunotherapy.
Int Immunopharmacol. 2024 Dec 5;142(Pt A):113147. doi: 10.1016/j.intimp.2024.113147. Epub 2024 Sep 12.
引用本文的文献
1
Efficient and effective identification of cancer neoantigens from tumor only RNA-seq.
NAR Genom Bioinform. 2025 Jul 11;7(3):lqaf026. doi: 10.1093/nargab/lqaf026. eCollection 2025 Sep.
2
Characterization of pritumumab in murine models and primate safety study.
Sci Rep. 2025 Mar 25;15(1):10178. doi: 10.1038/s41598-025-95360-9.
3
Ddx21 mutant peptide is an effective neoantigen in prophylactic lung cancer vaccines and activates long-term anti-tumor immunity.
Front Immunol. 2025 Feb 6;16:1500417. doi: 10.3389/fimmu.2025.1500417. eCollection 2025.
4
Immunogenic cryptic peptides dominate the antigenic landscape of ovarian cancer.
Sci Adv. 2025 Feb 21;11(8):eads7405. doi: 10.1126/sciadv.ads7405. Epub 2025 Feb 19.
5
Fabrication and functional validation of a hybrid biomimetic nanovaccine (HBNV) against -mutant melanoma.
Bioact Mater. 2024 Dec 27;46:347-364. doi: 10.1016/j.bioactmat.2024.12.023. eCollection 2025 Apr.
6
DeepHLApan: A Deep Learning Approach for the Prediction of Peptide-HLA Binding and Immunogenicity.
Methods Mol Biol. 2024;2809:237-244. doi: 10.1007/978-1-0716-3874-3_15.
7
Tumor neoantigens and tumor immunotherapies.
Aging Med (Milton). 2024 Apr 12;7(2):224-230. doi: 10.1002/agm2.12295. eCollection 2024 Apr.
8
Neoantigen vaccine and neoantigen-specific cell adoptive transfer therapy in solid tumors: Challenges and future directions.
Cancer Innov. 2022 Aug 30;1(2):168-182. doi: 10.1002/cai2.26. eCollection 2022 Aug.
9
Tumor Vaccines: Unleashing the Power of the Immune System to Fight Cancer.
Pharmaceuticals (Basel). 2023 Sep 29;16(10):1384. doi: 10.3390/ph16101384.
10
The Value of Microbes in Cancer Neoantigen Immunotherapy.
Pharmaceutics. 2023 Aug 14;15(8):2138. doi: 10.3390/pharmaceutics15082138.
本文引用的文献
1
Immunogenicity of somatic mutations in human gastrointestinal cancers.
Science. 2015 Dec 11;350(6266):1387-90. doi: 10.1126/science.aad1253. Epub 2015 Oct 29.
2
Isolation of neoantigen-specific T cells from tumor and peripheral lymphocytes.
J Clin Invest. 2015 Oct 1;125(10):3981-91. doi: 10.1172/JCI82416. Epub 2015 Sep 21.
3
Comprehensive analysis of cancer-associated somatic mutations in class I HLA genes.
Nat Biotechnol. 2015 Nov;33(11):1152-8. doi: 10.1038/nbt.3344.
4
Genomic correlates of response to CTLA-4 blockade in metastatic melanoma.
Science. 2015 Oct 9;350(6257):207-211. doi: 10.1126/science.aad0095. Epub 2015 Sep 10.
5
NY-ESO-1-specific TCR-engineered T cells mediate sustained antigen-specific antitumor effects in myeloma.
Nat Med. 2015 Aug;21(8):914-921. doi: 10.1038/nm.3910. Epub 2015 Jul 20.
6
Genomic Classification of Cutaneous Melanoma.
Cell. 2015 Jun 18;161(7):1681-96. doi: 10.1016/j.cell.2015.05.044.
7
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency.
N Engl J Med. 2015 Jun 25;372(26):2509-20. doi: 10.1056/NEJMoa1500596. Epub 2015 May 30.
8
Mutant MHC class II epitopes drive therapeutic immune responses to cancer.
Nature. 2015 Apr 30;520(7549):692-6. doi: 10.1038/nature14426. Epub 2015 Apr 22.
9
Adoptive cell transfer as personalized immunotherapy for human cancer.
Science. 2015 Apr 3;348(6230):62-8. doi: 10.1126/science.aaa4967.
10
Cancer immunotherapy. A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells.
Science. 2015 May 15;348(6236):803-8. doi: 10.1126/science.aaa3828. Epub 2015 Apr 2.
Zotero 插件